Citius Oncology Successfully Completes $9.0 Million Public Offering
Citius Oncology, Inc. (Nasdaq: CTOR) has successfully closed a public offering that raised approximately $9.0 million through the sale of shares of common stock and accompanying warrants. This offering consisted of 6,818,182 shares at a public offering price of $1.32 each, with the warrants being immediately exercisable and set to expire five years after issuance.
Strategic Use of Proceeds
The majority of the funds generated from this offering will be used to further the commercialization of LYMPHIR, the company's flagship product. LYMPHIR is a targeted treatment aimed at adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), and the proceeds will assist in fulfilling existing licensing agreements as well as for general corporate duties.
About LYMPHIR and Market Potential
LYMPHIR was designed to address a significant gap in the treatment options for CTCL. Following its approval by the FDA, management anticipates that the current market for LYMPHIR exceeds $400 million and is on a growth trajectory. They believe that this treatment will fulfill an urgent need for a therapy that currently lacks sufficient options on the market.
Company Growth and Competitive Edge
Citius Oncology is positioning itself firmly within the oncology landscape, armed with robust intellectual property protections that bolster its competitive stance. This includes orphan drug designation and pending patents related to immuno-oncology therapies, which can potentially be used alongside checkpoint inhibitors.
Role of Placement Agent
Maxim Group LLC served as the exclusive placement agent for this public offering. Their involvement has been instrumental in facilitating the successful execution of the offering.
About Citius Oncology and Citius Pharmaceuticals
Citius Oncology is a subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), recognized for its development of first-in-class critical care products. Citius Pharmaceuticals is dedicated to bringing innovative therapies to the market and recently announced multiple advancements in their product pipeline, including Mino-Lok®, which targets catheter-related bloodstream infections.
Future Plans and Focus Areas
Moving forward, both Citius Oncology and Citius Pharmaceuticals are committed to expanding their development efforts and addressing unmet medical needs in oncology and critical care. The proceeds from the recent public offering will significantly enhance these efforts.
Frequently Asked Questions
What was the total amount raised in the offering?
The offering raised approximately $9.0 million for Citius Oncology.
What is LYMPHIR's target condition?
LYMPHIR is targeted for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Who acted as the placement agent for the offering?
Maxim Group LLC acted as the exclusive placement agent in relation to this public offering.
What are the intended uses for the offering proceeds?
The net proceeds will primarily support LYMPHIR's commercialization and cover working capital and other corporate needs.
How is Citius Oncology positioned in the market?
Citius Oncology is positioned with a significant market opportunity and strong intellectual property protections, targeting a substantial growth area in oncology therapeutics.
